Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick

Area of Science:

• Oncology
• Pharmacology
• Inflammation Research

Background:

• Inflammation is closely linked to cancer development and progression.
• Key inflammatory mediators and related genes are often upregulated in various cancers.
• Current cancer therapeutics face limitations such as cytotoxicity and acquired tumor resistance.

Purpose of the Study:

• To explore the potential of Nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer therapy.
• To review novel NSAID derivatives as next-generation anti-cancer agents.
• To highlight the dual role of NSAIDs in treating inflammation and cancer.

Main Methods:

• Review of existing literature on NSAIDs and their role in cancer.
• Analysis of studies demonstrating NSAIDs' effect on cancer incidence, recurrence, and proliferation.
• Examination of emerging NSAID derivatives and their therapeutic potential.

Main Results:

• NSAIDs have demonstrated a reduction in the incidence, recurrence, and proliferation of various cancers, including colon, breast, lung, and pancreatic.
• Novel NSAID-based agents, such as NO- and H2S-releasing NSAIDs, NSAID-metal complexes, and phospho-NSAIDs, are under development.
• These advanced NSAID derivatives show potential for treating both inflammation and cancer.

Conclusions:

• NSAIDs represent a promising therapeutic strategy for cancer treatment.
• Next-generation NSAID derivatives offer a dual approach to combatting inflammation and cancer.
• Further research into NSAID derivatives could lead to improved cancer therapeutics with reduced side effects.